CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report released on Thursday morning. The firm issued a sell rating on the stock.

CEL-SCI Stock Performance

NYSE CVM opened at $0.30 on Thursday. CEL-SCI has a fifty-two week low of $0.29 and a fifty-two week high of $2.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. The firm has a market capitalization of $23.32 million, a P/E ratio of -0.63 and a beta of 0.67. The stock has a 50-day simple moving average of $0.39 and a two-hundred day simple moving average of $0.69.

Institutional Trading of CEL-SCI

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the period. Thoroughbred Financial Services LLC increased its stake in shares of CEL-SCI by 40.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after acquiring an additional 54,900 shares during the last quarter. Finally, Plotkin Financial Advisors LLC purchased a new position in shares of CEL-SCI during the 3rd quarter worth about $98,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.